An update on weight loss medication, tirzepatide

An update on weight loss medication, tirzepatide image

Home » News » An update on weight loss medication, tirzepatide

On 23 December 2024 the National Institute for Health and Care Excellence (NICE) published the Technology Appraisal in relation to tirzepatide (Mounjaro™) which is a medicine for managing obesity.

This medication is now available in Bedfordshire, Luton and Milton Keynes for certain groups of people with higher levels of obesity and at least four co-morbidities (other conditions). In the short term this medication will not be available directly from GP practices, although your GP may refer you to the specialist weight management services (SWMS) if you are eligible. 

People should only contact their GP if they are eligible. This means they have a BMI of 40 or higher and at least four of these additional conditions, which will already have been diagnosed by their GP or another medical professional:

  • Hypertension
  • Dyslipidaemia
  • Obstructive sleep apnoea
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Type 2 diabetes mellitus

Please see the FAQs below, which provide more information on what this means for Bedfordshire, Luton and Milton Keynes residents.

What is changing in the management of obesity because of NICE’s announcement?

Tirzepatide is currently prescribed for the treatment of type 2 diabetes but is now available for weight loss purposes but only as described above.

People in England over the age of 18 who are living with obesity and another weight-related health issues will be able to access the weight loss drug tirzepatide through specialist weight management services from spring 2025, but only if they fit the eligibility cohort

Who can access tirzepatide?

Initially this medication will be available for people living with obesity who have a body mass index (BMI) of 40 or over and four other weight-related health problems.   

Can I access tirzepatide straight away?

Introducing this new treatment to NICE’s estimated 3.4 million eligible patients requires the NHS in England to develop a completely new service for primary care and many healthcare professionals will need to be trained to deliver it.

A staged approach will help manage demand on existing healthcare services. This allows the safe prescribing of tirzepatide and the appropriate support for patients.

Tirzepatide will not be accessible to everyone who wishes to use it.  Tirzepatide will initially be offered to individuals facing the most significant health risks related to their weight, through referral from their GP to specialist weight management services.

How does tirzepatide work for weight loss?

Tirzepatide works by supressing appetite centres in the brain that control gut hormones. It decreases the appetite and slows the movement of food passing through the body, making you feel fuller for longer.

Clinical trials have shown tirzepatide can help people living with obesity lose up 20% of their starting body weight, depending on the dose and accompanying diet and lifestyle support.

Tirzepatide can only be prescribed by a healthcare professional alongside programmes which support people to lose weight and live healthier lives by making changes to their diet and physical activity.

Tirzepatide comes as an injection, which can be self-administered once a week.

What if a patient is already receiving tirzepatide treatment?

Patients can continue taking tirzepatide if they are prescribed it to manage their diabetes.

If patients are using tirzepatide they have acquired privately, they may be able to access the medication through an NHS prescription if they meet the NICE and NHS qualifying criteria. However, patients should not gain advantage over other patients waiting for NHS care.  More information about this will be made available in the new year.

Will everyone who is eligible have access to the drug?

Tirzepatide might not be suitable for everyone and not everyone who meets the eligibility criteria will want to use it to support their weight loss. A healthcare professional will discuss the most appropriate care and support, based on individual patient’s need. This could include behavioural support programmes, medical options including prescribing or bariatric surgery.

The NICE announcement mentions ‘wraparound’ care. What does this mean?

Any patient prescribed tirzepatide must participate in the specifically designed ‘wraparound’ care required by NICE guidance. This focuses on diet, nutrition and increasing physical activity. As NHS England develops the service, it will provide more details of the wraparound support offer for patients who qualify.  Patients cannot be prescribed tirzepatide if they do not wish to undertake the wraparound care support.

Will there be a cost to the patient for being prescribed tirzepatide?

Normal prescription charges will apply unless you are entitled to free NHS prescriptions (for example, because you have a medical exemption certificate).

View all news

Latest news and highlights

News

5 August 2025

Chairs which can lift people who fall in their own homes reduce…

A chair which helps lift people safely and quickly in an emergency after a fall has been proven to reduce avoidable ambulance call-outs and associated…

News

30 July 2025

Patients thanked for using NHS services appropriately during doctors’ strike

A local NHS leader has thanked patients for following recent advice to use services appropriately during strike action by resident doctors, but has warned that…

Case Study

28 July 2025

RoboPets help combat loneliness among elderly Milton Keynes residents

In April 2016, Laila Adatia founded Intrust Care Ltd, a home care provider based in Milton Keynes that now supports over 120 clients. In February 2025, Laila introduced four robotic…

News

22 July 2025

Patients urged to “please use NHS services wisely” ahead of planned NHS…

Patients in Bedfordshire, Luton and Milton Keynes have been urged to help the local NHS to preserve care for those who most need it, ahead of a national strike by…

News

22 July 2025

Local residents get answers to their cancer questions at shopping centre events

Hundreds of residents in Bedfordshire, Luton and Milton Keynes have received answers to their questions about cancer and cancer screening, following a series of outreach events across the region. Cancer…

News

18 July 2025

More than half of local people now have the NHS App on…

More than half of patients in Bedfordshire, Luton and Milton Keynes have now downloaded the NHS App, new figures show. More than half of local residents have now signed up…